Business Standard

Saturday, December 28, 2024 | 03:52 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Zydus Cadila Q1 consolidated net profit up 30% to Rs 587 cr

Revenue from operations up 14% to Rs 3,917 crore from Rs 3,424 crore in Q1F21

Zydus
Premium

Zydus has applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the company's Plasmid DNA Vaccine for human use after conducting the vaccine trial.

Vinay Umarji Ahmedabad
Cadila Healthcare Limited (Zydus Cadila) has posted a 29 per cent rise in its consolidated net profit on a year-on-year (YoY) basis at Rs 587 crore for the first quarter ended June 30, 2021. The company had registered a net profit of Rs 454 crore in the said quarter last year.

The company's consolidated revenue from operations rose by 14 per cent to Rs 3,917 crore in Q1 of FY 2021-22 from Rs 3,424 crore in Q1 of FY 2020-21.

Zydus Cadila's India business which consists of human formulations and consumer wellness and contributed to 50 per cent of consolidated revenues during

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in